A diagnostic dilemma: Atypical melanocytic lesions arising in the setting of treatment with the BRAF inhibitor, vemurafenib

oleh: Mary Clark, MD, Paul Imbriano, DO, Michael Harwood, MD, Klaus Busam, MD, Leslie Robinson-Bostom, MD

Format: Article
Diterbitkan: Elsevier 2022-06-01

Deskripsi

Subjek

BRAF inhibitor; hairy cell leukemia; melanoma; vemurafenib